EU expands Sotyktu label to adults with active psoriatic arthritis

Bristol Myers Squibb said the European Commission has approved Sotyktu (deucravacitinib) for adults with active psoriatic arthritis, either alone or with methotrexate, in patients who had an inadequate response to, or couldn’t tolerate, a prior disease-modifying antirheumatic drug. The decision expands Sotyktu’s EU label beyond its existing 2023 approval in moderate-to-severe plaque psoriasis and follows a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use in March 2026. (news.bms.com)

Why it matters: For veterinary professionals tracking the human immunology market, the approval adds momentum to TYK2 inhibition as a differentiated oral option in immune-mediated disease. Sotyktu’s psoriatic arthritis label is supported by the Phase 3 POETYK PsA program, and the expanded indication could further shape prescriber expectations around oral targeted therapies, lifecycle management, and competitive pressure across rheumatology and dermatology. While this is a human medicine development, it’s relevant as companion animal immunology continues to borrow scientific and commercial signals from adjacent human markets. (news.bms.com)

What to watch: National pricing and reimbursement decisions across Europe will likely determine how quickly the new indication translates into uptake. (news.bms.com)